Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Alzheimer's Research & Therapy
Published in: Alzheimer's Research & Therapy 1/2017

Open Access 01-12-2017 | Research

Antipsychotic prescribing for Alzheimer’s disease and related disorders in specialized settings from 2010 to 2014 in France: a repeated cross-sectional study

Authors: Karim Tifratene, Valeria Manera, Roxane Fabre, Auriane Gros, Susanne Thummler, Christian Pradier, Philippe Robert, Renaud David

Published in: Alzheimer's Research & Therapy | Issue 1/2017

Login to get access

Abstract

Background

Safety warnings from health authorities are currently intended to limit the use of antipsychotics (APs) in dementia-related conditions to treat neuropsychiatric symptoms, such as disturbing and/or delusional behaviors. The aim of this study is to investigate prevalence, correlates and trends of AP prescribing among people with dementia between 2010 and 2014 in the French population.

Methods

AP prescribing and associated factors among individuals with AD, mixed dementia and vascular dementia in the French National Alzheimer Database between 2010 and 2014 were analyzed using multivariate generalized estimating equations models (n = 199,549).

Results

In 2014, 7.7% of people with dementia were prescribed an AP. Compared with 2010 there was a 16% increase in AP use. Multivariate analysis showed a linear increase risk of prescription with an adjusted odds ratio (95% confidence interval) of 1.23 (1.17–1.30) in 2014 compared with 2010. Factors associated with AP prescribing were male gender, more severe cognitive decline and living in long-term care facilities. Older age and higher education were protective toward AP prescribing. The type of dementia did not have any influence on AP prescribing.

Conclusion

An increase in AP prescribing among individuals with dementia in French specialized settings over the last 5 years occurred despite safety warnings. This phenomenon suggests that alternative solutions for the management of behavioral and psychiatric symptoms in these populations are still urgently needed.
Appendix
Available only for authorised users
Literature
1.
Ballard CG, Gauthier S, Cummings JL, Brodaty H, Grossberg GT, Robert P, et al. Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol. 2009;5(5):245–55.CrossRefPubMed
2.
Burns A, Ballard C. A best practice guide for health and social care professionals. London: Alzheimer's Society; 2013.
3.
Bonner AF, Field TS, Lemay CA, Mazor KM, Andersen DA, Compher CJ, et al. Rationales that providers and family members cited for the use of antipsychotic medications in nursing home residents with dementia. J Am Geriatr Soc. 2015;63(2):302–8.CrossRefPubMed
4.
Langballe EM, Engdahl B, Nordeng H, Ballard C, Aarsland D, Selbaek G. Short- and long-term mortality risk associated with the use of antipsychotics among 26,940 dementia outpatients: a population-based study. Am J Geriatr Psychiatr. 2014;22(4):321–31.CrossRef
5.
Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293(5):596–608.CrossRefPubMed
6.
Maust DT, Kim HM, Seyfried LS, Chiang C, Kavanagh J, Schneider LS, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiat. 2015;72(5):438–45.CrossRef
7.
Foebel A, Ballokova A, Wellens NI, Fialova D, Milisen K, Liperoti R, et al. A retrospective, longitudinal study of factors associated with new antipsychotic medication use among recently admitted long-term care residents. BMC Geriatr. 2015;15:128.CrossRefPubMedPubMedCentral
8.
Rhee Y, Csernansky JG, Emanuel LL, Chang CG, Shega JW. Psychotropic medication burden and factors associated with antipsychotic use: an analysis of a population-based sample of community-dwelling older persons with dementia. J Am Geriatr Soc. 2011;59(11):2100–7.CrossRefPubMedPubMedCentral
9.
Rosenberg PB, Mielke MM, Han D, Leoutsakos JS, Lyketsos CG, Rabins PV, et al. The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease. Int J Geriatr Psychiatr. 2012;27(12):1248–57.CrossRef
10.
Lucas JA, Chakravarty S, Bowblis JR, Gerhard T, Kalay E, Paek EK, et al. Antipsychotic medication use in nursing homes: a proposed measure of quality. Int J Geriatr Psychiatr. 2014;29(10):1049–61.CrossRef
11.
Gallini A, Andrieu S, Donohue JM, Oumouhou N, Lapeyre-Mestre M, Gardette V. Trends in use of antipsychotics in elderly patients with dementia: impact of national safety warnings. Eur Neuropsychopharmacol. 2014;24(1):95–104.CrossRefPubMed
12.
Pitkala KH, Juola AL, Hosia H, Teramura-Gronblad M, Soini H, Savikko N, et al. Eight-year trends in the use of opioids, other analgesics, and psychotropic medications among institutionalized older people in Finland. J Am Med Dir Assoc. 2015;16(11):973–8.CrossRefPubMed
13.
Singh RR, Nayak R. Impact of FDA Black box warning on psychotropic drug use in noninstitutionalized elderly patients diagnosed with dementia: a retrospective study. J Pharm Pract. 2016;29(5):495–502.
14.
Mort JR, Sailor R, Hintz L. Partnership to decrease antipsychotic medication use in nursing homes: impact at the state level. S D Med. 2014;67(2):67–9.PubMed
15.
Reus VI, Fochtmann LJ, Eyler AE, Hilty DM, Horvitz-Lennon M, Jibson MD, et al. The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia. Am J Psychiatry. 2016;173(5):543–6.CrossRefPubMed
16.
Jennum P, Baandrup L, Ibsen R, Kjellberg J. Increased all-cause mortality with use of psychotropic medication in dementia patients and controls: a population-based register study. Eur Neuropsychopharmacol. 2015;25(11):1906–13.CrossRefPubMed
17.
Declercq T, Petrovic M, Azermai M, Vander Stichele R, De Sutter AI, van Driel ML, et al. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2013;3:CD007726.
18.
Azermai M, Petrovic M, Elseviers MM, Bourgeois J, Van Bortel LM, Vander Stichele RH. Systematic appraisal of dementia guidelines for the management of behavioural and psychological symptoms. Ageing Res Rev. 2012;11(1):78–86.CrossRefPubMed
19.
20.
21.
Spinney L. Alzheimer's disease funding and the French health system. Lancet Neurol. 2008;7(1):26–7.CrossRefPubMed
22.
Folstein MF, Folstein SE, McHugh PR. "Mini-mental test". A practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res. 1975;12:189–98.CrossRef
23.
Le Duff F, Develay AE, Quetel J, Lafay P, Schuck S, Pradier C, et al. The 2008-2012 French Alzheimer plan: description of the national Alzheimer information system. J Alzheimers Dis. 2012;29(4):891–902.PubMed
24.
Child A, Clarke A, Fox C, Maidment I. A pharmacy led program to review anti-psychotic prescribing for people with dementia. BMC Psychiatry. 2012;12:155.CrossRefPubMedPubMedCentral
25.
Barnes TR, Banerjee S, Collins N, Treloar A, McIntyre SM, Paton C. Antipsychotics in dementia: prevalence and quality of antipsychotic drug prescribing in UK mental health services. Br J Psychiatry. 2012;201(3):221–6.CrossRefPubMed
26.
Tuppin P, Cuerq A, Weill A, Ricordeau P, Allemand H. Alzheimer disease and other dementia in France: Identification, management and neuroleptic use (2007-2009). Rev Neurol. 2012;168(2):152–60.CrossRefPubMed
27.
Vida S, Monette J, Wilchesky M, Monette M, Friedman R, Nguyen A, et al. A long-term care center interdisciplinary education program for antipsychotic use in dementia: program update five years later. Int Psychogeriatr. 2012;24(4):599–605.CrossRefPubMed
28.
Lustenberger I, Schupbach B, von Gunten A, Mosimann U. Psychotropic medication use in Swiss nursing homes. Swiss Med Wkly. 2011;141:w13254.PubMed
29.
Rattinger GB, Burcu M, Dutcher SK, Chhabra PT, Rosenberg PB, Simoni-Wastila L, et al. Pharmacotherapeutic management of dementia across settings of care. J Am Geriatr Soc. 2013;61(5):723–33.CrossRefPubMedPubMedCentral
30.
Alessi-Severini S, Dahl M, Schultz J, Metge C, Raymond C. Prescribing of psychotropic medications to the elderly population of a Canadian province: a retrospective study using administrative databases. PeerJ. 2013;1:e168.CrossRefPubMedPubMedCentral
31.
Huber M, Kolzsch M, Rapp MA, Wulff I, Kalinowski S, Bolbrinker J, et al. Antipsychotic drugs predominate in pharmacotherapy of nursing home residents with dementia. Pharmacopsychiatry. 2012;45(5):182–8.PubMed
32.
Lopez OL, Becker JT, Chang YF, Sweet RA, Aizenstein H, Snitz B, et al. The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's disease. Am J Psychiatry. 2013;170(9):1051–8.CrossRefPubMedPubMedCentral
33.
Afram B, Stephan A, Verbeek H, Bleijlevens MH, Suhonen R, Sutcliffe C, et al. Reasons for institutionalization of people with dementia: informal caregiver reports from 8 European countries. J Am Med Dir Assoc. 2014;15(2):108–16.CrossRefPubMed
34.
de Mauleon A, Sourdet S, Renom-Guiteras A, Gillette-Guyonnet S, Leino-Kilpi H, Karlsson S, et al. Associated factors with antipsychotic use in long-term institutional care in eight European countries: results from the RightTimePlaceCare study. J Am Med Dir Assoc. 2014;15(11):812–8.CrossRefPubMed
35.
Tartaglia MC, Hu B, Mehta K, Neuhaus J, Yaffe K, Miller BL, et al. Demographic and neuropsychiatric factors associated with off-label medication use in frontotemporal dementia and Alzheimer's disease. Alzheimer Dis Assoc Disord. 2014;28(2):182–9.CrossRefPubMedPubMedCentral
36.
Wastesson JW, Ringback Weitoft G, Johnell K. Educational disparities in antipsychotic drug use among older people with and without dementia in Sweden. Acta Psychiatr Scand. 2015;132(1):20–8.CrossRefPubMed
37.
Bell JS, Ilomaki J, O'Connor DW. Why are more highly educated people with dementia less likely to be prescribed antipsychotics? Acta Psychiatr Scand. 2015;132(1):1–3.CrossRefPubMed
38.
Gulla C, Selbaek G, Flo E, Kjome R, Kirkevold O, Husebo BS. Multi-psychotropic drug prescription and the association to neuropsychiatric symptoms in three Norwegian nursing home cohorts between 2004 and 2011. BMC Geriatr. 2016;16(1):115.CrossRefPubMedPubMedCentral
39.
Kim H, Whall AL. Factors associated with psychotropic drug usage among nursing home residents with dementia. Nurs Res. 2006;55(4):252–8.CrossRefPubMed
40.
Franchi C, Tettamanti M, Marengoni A, Bonometti F, Pasina L, Cortesi L, et al. Changes in trend of antipsychotics prescription in patients treated with cholinesterase inhibitors after warnings from Italian Medicines Agency. Results from the EPIFARM-Elderly Project. Eur Neuropsychopharmacol. 2012;22(8):569–77.CrossRefPubMed
41.
Sultana J, Fontana A, Giorgianni F, Pasqua A, Cricelli C, Spina E, et al. The effect of safety warnings on antipsychotic drug prescribing in elderly persons with dementia in the United Kingdom and Italy: a population-based study. CNS Drugs. 2016;30(11):1097–109.CrossRefPubMed
42.
Taipale H, Koponen M, Tanskanen A, Tolppanen AM, Tiihonen J, Hartikainen S. High prevalence of psychotropic drug use among persons with and without Alzheimer's disease in Finnish nationwide cohort. Eur Neuropsychopharmacol. 2014;24(11):1729–37.CrossRefPubMed
43.
Lachaine J, Beauchemin C, Crochard A, Bineau S. The impact of memantine and cholinesterase inhibitor initiation for Alzheimer disease on the use of antipsychotic agents: analysis using the Regie de l'Assurance Maladie du Quebec database. Can J Psychiatry. 2013;58(4):195–200.CrossRefPubMed
44.
Martinez C, Jones RW, Rietbrock S. Trends in the prevalence of antipsychotic drug use among patients with Alzheimer's disease and other dementias including those treated with antidementia drugs in the community in the UK: a cohort study. BMJ Open. 2013;3(1):1–12.
45.
Reber KC, Piening S, Wieringa JE, Straus SM, Raine JM, de Graeff PA, et al. When direct health-care professional communications have an impact on inappropriate and unsafe use of medicines. Clin Pharmacol Ther. 2013;93(4):360–5.CrossRefPubMed
46.
Ballard C, Lana MM, Theodoulou M, Douglas S, McShane R, Jacoby R, et al. A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). PLoS Med. 2008;5(4):e76.CrossRefPubMedPubMedCentral
47.
Sultana J, Trifiro G. Drug safety warnings: a message in a bottle. J Drug Dev Res. 2014;1(1):1004.
48.
Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology. 2007;18(6):805–35.CrossRefPubMed
Metadata
Title
Antipsychotic prescribing for Alzheimer’s disease and related disorders in specialized settings from 2010 to 2014 in France: a repeated cross-sectional study
Authors
Karim Tifratene
Valeria Manera
Roxane Fabre
Auriane Gros
Susanne Thummler
Christian Pradier
Philippe Robert
Renaud David
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Alzheimer's Research & Therapy / Issue 1/2017
Electronic ISSN: 1758-9193
DOI
https://doi.org/10.1186/s13195-017-0256-8

Other articles of this Issue 1/2017

Alzheimer's Research & Therapy 1/2017 Go to the issue

Research

Optimizing medication appropriateness in older adults: a randomized clinical interventional trial to decrease anticholinergic burden

Research

Association between chronic periodontitis and the risk of Alzheimer’s disease: a retrospective, population-based, matched-cohort study

Research

No added diagnostic value of non-phosphorylated tau fraction (p-taurel) in CSF as a biomarker for differential dementia diagnosis

Research

Anticholinergic drugs and functional, cognitive impairment and behavioral disturbances in patients from a memory clinic with subjective cognitive decline or neurocognitive disorders

Research

Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment

Research

ERβ and ApoE isoforms interact to regulate BDNF–5-HT2A signaling and synaptic function in the female brain